Park Place Capital’s AbbVie ABBV Stock Holding History

Park Place Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Buy	10,274 +4,855	+90%	+$1.08M	0.45%	39
2025 Q4	$1.24M	Sell	5,419 -584	-10%	-$133K	0.26%	65
2025 Q3	$1.39M	Buy	6,003 +10	+0.2%	+$2.04K	0.29%	61
2025 Q2	$1.14M	Sell	5,993 -3,307	-36%	-$615K	0.26%	70
2025 Q1	$1.95M	Sell	9,300 -1,914	-17%	-$372K	0.53%	39
2024 Q4	$1.99M	Buy	11,214 +605	+6%	+$111K	0.56%	38
2024 Q3	$2.09M	Sell	10,609 -1,471	-12%	-$275K	0.6%	34
2024 Q2	$2.07M	Sell	12,080 -2,022	-14%	-$335K	0.66%	34
2024 Q1	$2.57M	Sell	14,102 -4,332	-24%	-$747K	0.92%	25
2023 Q4	$2.86M	Buy	18,434 +979	+6%	+$143K	1.14%	15
2023 Q3	$2.6M	Buy	17,455 +734	+4%	+$108K	0.76%	25
2023 Q2	$2.25M	Sell	16,721 -2,213	-12%	-$325K	0.64%	31
2023 Q1	$3.02M	Buy	18,934 +508	+3%	+$77.7K	0.85%	22
2022 Q4	$2.98M	Buy	+18,426	New	+$2.83M	0.84%	20

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Park Place Capital's ABBV Position: Q1 2026 in Review

Park Place Capital increased its AbbVie (ABBV) stake by 90% in Q1 2026, buying an estimated $1.08M and bringing the position to 10,274 shares worth $2.23M. The position accounts for 0.45% of the portfolio, ranked #39.

Park Place Capital first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.02M in Q1 2023. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Park Place Capital held 10,274 shares of AbbVie worth $2.23M as of Q1 2026.
Park Place Capital bought 4,855 AbbVie shares in Q1 2026, an estimated $1.08M.
AbbVie made up 0.45% of Park Place Capital's portfolio in Q1 2026, its #39 holding.
Park Place Capital first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Park Place Capital's AbbVie position peaked at $3.02M in Q1 2023.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.